{
    "2018-08-31": [
        [
            {
                "time": "2018-07-31",
                "original_text": "Analyzing Eli Lillyâ€™s Q2 2018 Revenue Trend",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Q2",
                        "Revenue",
                        "Trend"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-01",
                "original_text": "Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "Roundup",
                        "Approval",
                        "NVS",
                        "ABBV",
                        "Cancer",
                        "Drugs",
                        "MRK",
                        "HIV"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-02",
                "original_text": "Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "Roundup",
                        "Approval",
                        "NVS",
                        "ABBV",
                        "Cancer",
                        "Drugs",
                        "MRK",
                        "HIV"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-03",
                "original_text": "4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline",
                "features": {
                    "keywords": [
                        "Large",
                        "Cap",
                        "Pharma",
                        "Stocks",
                        "Focus",
                        "Robust",
                        "Cancer",
                        "Pipeline"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}